Pfizer, one of the Triangle ’s largest employers, to close two facilities in NC
(Source: Reuters: Health)
Source: Reuters: Health - October 28, 2023 Category: Consumer Health News Source Type: news

Pfizer announces closure of facilities in Morrisville, Durham
Friday, Pfizer confirmed the closing of two of its facilities in the Triangle. According to the pharmaceutical company, the Kit Creek facility in Morrisville, North Carolina, and the Durham Clinical Manufacturing Facility will be closing. However, the company's largest North Carolina facilities in…#pfizer #triangle #kitcreek #morrisville #northcarolina #sanford #rockymount (Source: Reuters: Health)
Source: Reuters: Health - October 28, 2023 Category: Consumer Health News Source Type: news

FDA Should Recall'Adulterated' Pfizer COVID-19 Vaccine: Robert Malone
FDA Should Recall 'Adulterated' Pfizer COVID-19 Vaccine: Robert Malone Authored by Zachary Stieber via The Epoch Times (emphasis ours), Pfizer's COVID-19 vaccine is adulterated due to the undisclosed presence of a DNA sequence, experts say. A health worker fills a syringe with a Pfizer-BioNTech…#fda #covid19vaccine #robertmalone #zacharystieber #epochtimes #pfizer #simian #kevinmckernan #davidwiseman #johnsonjohnson (Source: Reuters: Health)
Source: Reuters: Health - October 28, 2023 Category: Consumer Health News Source Type: news

A new Covid variant has become dominant amid slow uptake of the updated shots
A new Covid variant has become dominant in the U.S., but relatively few people have thus far gotten the new shots that could offer some protection against it. The variant, called HV.1, replaced EG.5 as the country's most prevalent this week, according to data released Friday by the Centers for…#hv1 #xbb #pfizer #xbb15 #scottroberts #yalemedicine #cdc #danbarouch #boston #barouch (Source: Reuters: Health)
Source: Reuters: Health - October 27, 2023 Category: Consumer Health News Source Type: news

COVID-19 treatments to enter the market with a hefty price tag
The COVID-19 treatments millions of Americans have taken for free from the federal government will enter the private market next week with a hefty price tag. Pharmaceutical giant Pfizer is setting the price for a five-day treatment of Paxlovid at $1,390, but Americans can still access the pills at…#pfizer #merck #medicaid #medicare #tommurphy #indianapolis (Source: Reuters: Health)
Source: Reuters: Health - October 27, 2023 Category: Consumer Health News Source Type: news

Roche enters into a definitive agreement to acquire Telavant including rights to novel TL1A directed antibody (RVT-3101) for the treatment of inflammatory bowel disease from Roivant
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced the entry into a definitive agreement to acquire Telavant Holdings, Inc. (Telavant), a Roivant company, owned by Roivant Sciences Ltd. and Pfizer Inc.. The agreement includes the development, manufacturing and commercialisation rights in the US and Japan for Telavant's RVT-3101, a novel TL1A directed antibody. (Source: World Pharma News)
Source: World Pharma News - October 27, 2023 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

FDA says getting Covid shot on same day as certain flu vaccines may raise risk of strokes in elderly people - while children aged 2-5 slightly more likely to suffer seizures after a coronavirus vaccine
Two new analyses by the US FDA have flagged up possible health concerns about the Covid shots made by Pfizer and Moderna. But the agency stresses the links are not definitive. (Source: the Mail online | Health)
Source: the Mail online | Health - October 26, 2023 Category: Consumer Health News Source Type: news

How to Get RSV Vaccines to Those Who Need Them Most
The world is entering a new era of vaccines. Following the success of COVID-19 mRNA shots, scientists have a far greater capacity to tailor shots to a virus’s structure, putting a host of new vaccines on the horizon. The most recent arrivals are several new immunizations against respiratory syncytial virus, or RSV. These shots are welcome since RSV can be dangerous, even deadly, in the very old and very young. But the shots, produced by Pfizer and GlaxoSmithKline, are also expensive, costing about $300 for those directed at adults, and up to $1,000 for one of the shots, a monoclonal antibody rather than a tradi...
Source: TIME: Health - October 26, 2023 Category: Consumer Health News Authors: Elisabeth Rosenthal Tags: Uncategorized Drugs Source Type: news

mRNA Vaccine Cuts COVID-Related Guillain-Barr é Risk mRNA Vaccine Cuts COVID-Related Guillain-Barr é Risk
COVID-19 increases the risk for Guillain-Barr é syndrome sixfold, while getting the Pfizer mRNA vaccine lowers risk.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - October 26, 2023 Category: Drugs & Pharmacology Tags: Neurology & Neurosurgery News Source Type: news

Is Moderna Stock A Buy After Reiterating Its Guide After Pfizer's Cut?
stock collapsed in mid-October after rival Pfizer (PFE) slashed about $9 billion from its full-year outlook due to declining demand for Covid products. But Moderna retained its guide for $6 billion to $8 billion in full-year sales of Covid vaccine, Spikevax. The company noted the outlook,…#pfe #spikevax #nvax #sanofi #gsk #merck #immatics #carsgen #moderna #fda (Source: Reuters: Health)
Source: Reuters: Health - October 26, 2023 Category: Consumer Health News Source Type: news

FDA Approves Pfizer ’s Vaccine for Meningococcal Disease
The U.S. Food and Drug Administration has approved Pfizer’s application for Penbraya, a vaccine for people 10 through 25 that will offer protection against the five main kinds of bacteria that cause meningitis and blood poisoning. (Source: WebMD Health)
Source: WebMD Health - October 23, 2023 Category: Consumer Health News Source Type: news

Elon Musk has a blunt take on capitalism
Elon Musk, the Chief Executive of Tesla (TSLA) - Get Free Report and the owner of around half a dozen other companies spanning the technology and software sector, is the world's richest man by a margin of nearly $50 billion. Musk, worth $204 billion after taking a multi-billion-dollar loss in the…#elonmusk #tesla #johannorberg #norberg #catoinstitute #tenorht #pfizer #pewresearch #twitter #usd (Source: Reuters: Health)
Source: Reuters: Health - October 23, 2023 Category: Consumer Health News Source Type: news

FDA approves PENBRAYA ™, the first and only vaccine for the prevention of the five most common serogroups causing meningococcal disease in adolescents
Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved PENBRAYA™ (meningococcal groups A, B, C, W and Y vaccine), the first and only pentavalent vaccine that provides coverage against the most common serogroups causing meningococcal disease in adolescents and young adults 10 through 25 years of age. (Source: World Pharma News)
Source: World Pharma News - October 23, 2023 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche enters into a definitive agreement to acquire Telavant including rights to novel TL1A directed antibody (RVT-3101) for the treatment of inflammatory bowel disease from Roivant
Roche will gain the rights to develop, manufacture and commercialise RVT-3101 in the US and Japan for the treatment of inflammatory bowel disease and potentially multiple other diseasesRVT-3101 is a Phase 3-ready antibody with first-in-class and best-in-disease potential, a novel mode of action and strong Phase 2b data in ulcerative colitisRoche will also obtain an option to enter into a global collaboration with Pfizer on a next-generation p40/TL1A directed bispecific antibody, currently in Phase 1Under the terms of the agreement, Roche will pay a purchase price of US$ 7.1 billion upfront and a near-term milestone payment...
Source: Roche Investor Update - October 23, 2023 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche enters into a definitive agreement to acquire Telavant including rights to novel TL1A directed antibody (RVT-3101) for the treatment of inflammatory bowel disease from Roivant
Roche will gain the rights to develop, manufacture and commercialise RVT-3101 in the US and Japan for the treatment of inflammatory bowel disease and potentially multiple other diseasesRVT-3101 is a Phase 3-ready antibody with first-in-class and best-in-disease potential, a novel mode of action and strong Phase 2b data in ulcerative colitisRoche will also obtain an option to enter into a global collaboration with Pfizer on a next-generation p40/TL1A directed bispecific antibody, currently in Phase 1Under the terms of the agreement, Roche will pay a purchase price of US$ 7.1 billion upfront and a near-term milestone payment...
Source: Roche Media News - October 23, 2023 Category: Pharmaceuticals Source Type: news